Beijing Bohui Innovation Biotechnology Group Co., Ltd. (SHE:300318)
China · Delayed Price · Currency is CNY 5.67
-0.24 (-4.06%)
May 12, 2026, 3:04 PM CST
SHE:300318 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 812.78 | 824.58 | 817.05 | 998.91 | 751.6 | 682.18 |
Other Revenue | - | - | 34.64 | 46.52 | 44.33 | 32.57 |
| 812.78 | 824.58 | 851.69 | 1,045 | 795.93 | 714.75 | |
Revenue Growth (YoY) | 2.71% | -3.18% | -18.53% | 31.35% | 11.36% | -3.25% |
Cost of Revenue | 507.57 | 498.4 | 434.16 | 593.97 | 542.42 | 422.28 |
Gross Profit | 305.21 | 326.17 | 417.53 | 451.46 | 253.51 | 292.47 |
Selling, General & Admin | 243.95 | 245.3 | 286 | 306.15 | 269.64 | 308.94 |
Research & Development | 62.9 | 64.92 | 52.52 | 69.2 | 64.78 | 81.48 |
Other Operating Expenses | 10.06 | 9 | 14.45 | 15.84 | 15.96 | 13.41 |
Operating Expenses | 316.91 | 319.22 | 354.68 | 392.5 | 352.67 | 404.44 |
Operating Income | -11.7 | 6.95 | 62.86 | 58.97 | -99.16 | -111.98 |
Interest Expense | - | - | -28.96 | -27.62 | -42.25 | -45.06 |
Interest & Investment Income | - | - | 1.92 | 4.78 | 0.51 | 4.97 |
Currency Exchange Gain (Loss) | - | - | -1.29 | -0.45 | -1.07 | -0.45 |
Other Non Operating Income (Expenses) | -78.29 | -88.42 | -6.42 | -8.74 | -6.79 | -3.98 |
EBT Excluding Unusual Items | -89.99 | -81.47 | 28.1 | 26.94 | -148.76 | -156.5 |
Impairment of Goodwill | - | - | - | - | -15.92 | -340.68 |
Gain (Loss) on Sale of Investments | -10.65 | -9.18 | - | - | - | - |
Gain (Loss) on Sale of Assets | 0.23 | -0.37 | 0.12 | 1.11 | 31.97 | 0.14 |
Asset Writedown | -79.46 | -80.29 | -2.55 | -3.31 | -1.61 | -20.43 |
Other Unusual Items | - | - | -5.76 | 8.98 | 0.55 | 13.29 |
Pretax Income | -179.86 | -171.31 | 19.91 | 33.73 | -133.78 | -504.18 |
Income Tax Expense | 0.88 | 0.69 | 11.23 | 18.05 | 4.39 | 1.61 |
Earnings From Continuing Operations | -180.74 | -172.01 | 8.68 | 15.68 | -138.17 | -505.79 |
Minority Interest in Earnings | 85.58 | 80.08 | 0.57 | -40.61 | 59.73 | 183.61 |
Net Income | -95.15 | -91.92 | 9.25 | -24.93 | -78.44 | -322.18 |
Net Income to Common | -95.15 | -91.92 | 9.25 | -24.93 | -78.44 | -322.18 |
Shares Outstanding (Basic) | 819 | 817 | 818 | 817 | 817 | 817 |
Shares Outstanding (Diluted) | 819 | 817 | 818 | 817 | 817 | 817 |
Shares Change (YoY) | 0.30% | -0.14% | 0.11% | 0.03% | 0.03% | 0.15% |
EPS (Basic) | -0.12 | -0.11 | 0.01 | -0.03 | -0.10 | -0.39 |
EPS (Diluted) | -0.12 | -0.11 | 0.01 | -0.03 | -0.10 | -0.39 |
Free Cash Flow | -294.97 | -292.09 | -227.64 | -60.53 | -120.74 | -366.17 |
Free Cash Flow Per Share | -0.36 | -0.36 | -0.28 | -0.07 | -0.15 | -0.45 |
Gross Margin | 37.55% | 39.56% | 49.02% | 43.18% | 31.85% | 40.92% |
Operating Margin | -1.44% | 0.84% | 7.38% | 5.64% | -12.46% | -15.67% |
Profit Margin | -11.71% | -11.15% | 1.09% | -2.38% | -9.86% | -45.08% |
Free Cash Flow Margin | -36.29% | -35.42% | -26.73% | -5.79% | -15.17% | -51.23% |
EBITDA | 76.67 | 96.28 | 156 | 158.74 | 6.53 | -7.09 |
EBITDA Margin | 9.43% | 11.68% | 18.32% | 15.18% | 0.82% | -0.99% |
D&A For EBITDA | 88.37 | 89.33 | 93.15 | 99.77 | 105.69 | 104.89 |
EBIT | -11.7 | 6.95 | 62.86 | 58.97 | -99.16 | -111.98 |
EBIT Margin | -1.44% | 0.84% | 7.38% | 5.64% | -12.46% | -15.67% |
Effective Tax Rate | - | - | 56.41% | 53.51% | - | - |
Revenue as Reported | - | - | 851.69 | 1,045 | 795.93 | 714.75 |
Advertising Expenses | - | - | 15.2 | 17.36 | 14.71 | 31.57 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.